Literature DB >> 26759266

Quality assessment of osteoporosis clinical practice guidelines for physical activity and safe movement: an AGREE II appraisal.

James Jacob Armstrong1, Isabel Braganca Rodrigues2, Tom Wasiuta3, Joy C MacDermid4.   

Abstract

UNLABELLED: Many osteoporosis clinical practice guidelines are published, and the extent to which physical activity and safe movement is addressed varies. To better inform clinical decision-making, a quality assessment and structured analysis of recommendations was undertaken. Guideline quality varied substantially, and improvement is necessary in physical activity and safe movement recommendations.
PURPOSE: The purpose of the present study is to survey available osteoporosis clinical practice guidelines (CPGs) containing physical activity and safe movement recommendations in order to assess the methodological quality with which they were developed. An analysis of the various physical activity and safe movement recommendations was conducted to determine variability between CPGs.
METHODS: An online literature search revealed 19 CPGs meeting our inclusion criteria. Three independent scorers evaluated CPG quality using the Appraisal of Guidelines for Research and Evaluation version II (AGREE II) instrument. Two separate individuals used a standard table to extract relevant recommendations.
RESULTS: Intra-reviewer AGREE II score agreement ranged from fair to good (intra-class correlation coefficient (ICC) = 0.34 to 0.65). The quality of the 19 included CPGs was variable (AGREE sub-scores: 14 to 100%). CPGs scored higher in the "scope and purpose" and "clarity of presentation" domains. They scored the lowest in "applicability" and "editorial independence." Four CPGs were classified as high quality, ten average quality, and five low quality. Most CPGs recommended weight-bearing, muscle-strengthening, and resistance exercises. Information on exercise dosage, progression, and contraindications was often absent. Immobility and movements involving spinal flexion and/or torsion were discouraged.
CONCLUSIONS: There were several high-quality CPGs; however, variability in quality and lack of specific parameters for implementation necessitates caution and critical examination by readers. CPG development groups should pay special attention to the clinical applicability of their CPGs as well as fully disclosing conflicts of interest. CPGs were in general an agreement regarding safe physical activity and safe movement recommendations. However, recommendations were often vague and the more specific recommendations were inconsistent between CPGs.

Entities:  

Keywords:  AGREE; Exercise; Guidelines; Osteoporosis; Physical activity; Safe movement

Mesh:

Year:  2016        PMID: 26759266     DOI: 10.1007/s11657-016-0260-9

Source DB:  PubMed          Journal:  Arch Osteoporos            Impact factor:   2.617


  18 in total

1.  Clinical practice guidelines on ultrasound-guided fine needle aspiration biopsy of thyroid nodules: a critical appraisal using AGREE II.

Authors:  Salvatore Gitto; Sotirios Bisdas; Ilaria Emili; Luca Nicosia; Lorenzo Carlo Pescatori; Kunwar Bhatia; Ravi K Lingam; Francesco Sardanelli; Luca Maria Sconfienza; Giovanni Mauri
Journal:  Endocrine       Date:  2019-03-22       Impact factor: 3.633

2.  The Quality of Six Clinical Practice Guidelines in Health and Social Sciences: Are We on the Right Track?

Authors:  Catherine Hébert; Kia Watkins-Martin; Gabrielle Ciquier; Michelle Azzi; Martin Drapeau
Journal:  Adm Policy Ment Health       Date:  2021-04-18

3.  Osteoporosis Management in Ankylosing Spondylitis.

Authors:  Alicia M Hinze; Grant H Louie
Journal:  Curr Treatm Opt Rheumatol       Date:  2016-10-05

Review 4.  Facilitators and barriers to exercise adherence in patients with osteopenia and osteoporosis: a systematic review.

Authors:  I B Rodrigues; J J Armstrong; J D Adachi; J C MacDermid
Journal:  Osteoporos Int       Date:  2016-10-06       Impact factor: 4.507

Review 5.  Pediatric traumatic brain injury prehospital guidelines: a systematic review and appraisal.

Authors:  Zhe Wang; Dellvin Nguonly; Rebecca Y Du; Roxanna M Garcia; Sandi K Lam
Journal:  Childs Nerv Syst       Date:  2021-09-23       Impact factor: 1.475

6.  A critical appraisal of the quality of adult dual-energy X-ray absorptiometry guidelines in osteoporosis using the AGREE II tool: An EuroAIM initiative.

Authors:  Carmelo Messina; Bianca Bignotti; Alberto Bazzocchi; Catherine M Phan; Alberto Tagliafico; Giuseppe Guglielmi; Francesco Sardanelli; Luca Maria Sconfienza
Journal:  Insights Imaging       Date:  2017-04-21

7.  A critical appraisal of the quality of adult musculoskeletal ultrasound guidelines using the AGREE II tool: an EuroAIM initiative.

Authors:  Carmelo Messina; Bianca Bignotti; Alberto Tagliafico; Davide Orlandi; Angelo Corazza; Francesco Sardanelli; Luca Maria Sconfienza
Journal:  Insights Imaging       Date:  2017-07-28

8.  The quality of guidelines in non-pharmacological prevention and management of chemotherapy-induced neuropathy: A review.

Authors:  Shahin Salarvand; Simin Hemati; Payman Adibi; Fariba Taleghani
Journal:  Oncol Rev       Date:  2018-10-18

9.  Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology.

Authors:  Umberto Tarantino; Giovanni Iolascon; Luisella Cianferotti; Laura Masi; Gemma Marcucci; Francesca Giusti; Francesca Marini; Simone Parri; Maurizio Feola; Cecilia Rao; Eleonora Piccirilli; Emanuela Basilici Zanetti; Noemi Cittadini; Rosaria Alvaro; Antimo Moretti; Dario Calafiore; Giuseppe Toro; Francesca Gimigliano; Giuseppina Resmini; Maria Luisa Brandi
Journal:  J Orthop Traumatol       Date:  2017-11

10.  Protocol of an interdisciplinary consensus project aiming to develop an AGREE II extension for guidelines in surgery.

Authors:  George A Antoniou; Dimitris Mavridis; Sofia Tsokani; Manuel López-Cano; Iván D Flórez; Melissa Brouwers; Sheraz R Markar; Gianfranco Silecchia; Nader K Francis; Stavros A Antoniou
Journal:  BMJ Open       Date:  2020-08-11       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.